The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of allergy, immunology, and infectious diseases including HIV/AIDS and its co-morbidities and co-infections, mental health, and selected neurological disorders.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of innovative technologies that may advance progress toward more effective cell replacement therapies for type 1 diabetes (T1D).

This topic area is aimed at developing technologies for ultrafast lasers capable of high average power (kilowatt-class) operating at the high electrical-to-optical efficiency (>20%) needed for advanced accelerator applications.

An attractive fusion energy source will require the development of superconducting magnets and materials as well as technologies that can withstand the high levels of surface heat flux and neutron wall loads expected for the in-vessel components of future fusion energy systems. These technologies and materials will need to be substantially advanced relative to today's capabilities in order to achieve safe, reliable, economic, and environmentally-benign operation of fusion energy systems.

An attractive fusion energy source will require the development of superconducting magnets and materials as well as technologies that can withstand the high levels of surface heat flux and neutron wall loads expected for the in-vessel components of future fusion energy systems. These technologies and materials will need to be substantially advanced relative to today's capabilities in order to achieve safe, reliable, economic, and environmentally-benign operation of fusion energy systems